0000000000038354

AUTHOR

Mojca Jensterle

showing 6 related works from this author

Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study

2021

Abstract Aim We evaluated the effect of the latest GLP-1 RA semaglutide on tongue fat storage in obese women. Design. We conducted a randomized single-blind, pilot study. Methods Twenty-five obese women with polycystic ovary syndrome (PCOS) (33.7 ± 5.3 years, body mass index (BMI) 36.1 ± 3.9 kg/m2, mean ± SD) were randomized to semaglutide 1.0 mg or placebo for 16 weeks. We quantified tongue volume and its fat tissue and fat proportion by magnetic resonance imaging. Results Tongue fat tissue and fat proportion significantly reduced after semaglutide vs placebo (-1.94 ± 5.51 vs. + 3.12 ± 4.87 cm3, p = 0.022, and −0.02 ± 0.07 vs. 0.04 ± 0.06, p = 0.010, respectively). Correlation analysis rev…

Adultmedicine.medical_specialtyWaistEndocrinology Diabetes and MetabolismGlucagon-Like PeptidesAdipose tissuePilot ProjectsPlaceboGastroenterologyEndocrinologyDouble-Blind MethodTongueTongueInternal medicineInternal MedicinemedicineHumansSingle-Blind MethodObesityGlucagon like peptide-1 receptor Obesity PCOS Semaglutide Tongue fat Adult Double-Blind Method Female Glucagon-Like Peptides Humans Obesity Pilot Projects Single-Blind Method Adiposity TongueAdipositybusiness.industrySemaglutideGeneral Medicinemedicine.diseaseObesityPolycystic ovarymedicine.anatomical_structureFemalebusinessBody mass index
researchProduct

The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO I…

2022

Coronavirus disease 2019 (COVID-19) is a highly heterogeneous disease regarding severity, vulnerability to infection due to comorbidities, and treatment approaches. The hypothalamic–pituitary–adrenal (HPA) axis has been identified as one of the most critical endocrine targets of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that might significantly impact outcomes after infection. Herein we review the rationale for glucocorticoid use in the setting of COVID-19 and emphasize the need to have a low index of suspicion for glucocorticoid-induced adrenal insufficiency, adjusting for the glucocorticoid formulation used, dose, treatment duration, and underlying health problems. We a…

Hypothalamo-Hypophyseal SystemHydrocortisoneSARS-CoV-2Organic ChemistryCOVID-19Pituitary-Adrenal SystemGeneral MedicineCatalysisComputer Science ApplicationsInorganic ChemistrySARS-CoV-2 adrenal insufficiency glucocorticoids hypercortisolism hypothalamic–pituitary–adrenal axisHumansPhysical and Theoretical ChemistryMolecular BiologyGlucocorticoidsSpectroscopyInternational journal of molecular sciences
researchProduct

Glucose transporter 4 mRNA expression in subcutaneous adipose tissue of women with PCOS remains unchanged despite metformin withdrawal: is there a ce…

2021

Purpose: Metformin induces GLUT-4 mRNA expression in insulin target tissues in PCOS. It is unclear how long this impact is sustained after withdrawal of metformin. We aimed to compare the effect of metformin withdrawal on GLUT-4 mRNA expression in subcutaneous adipose tissue after prior short (ST, 1 year, N = 11) and long term (LT, at least 3 years, N = 13) treatment in obese PCOS women. Methods: At baseline and 6 months after withdrawal, biopsy of subcutaneous adipose tissue followed by quantitative PCR analysis was performed to determine GLUT-4 mRNA expression. Results: We found no time/effect differences in GLUT-4 mRNA expression in ST (2-dCt at baseline 0.42 (0.16–0.48) vs 2-dCt after 6…

medicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMrna expressionGlucose Transport Proteins FacilitativeSubcutaneous FatAdipose tissueQuantitative PCR analysisEndocrinologyInternal medicineBiopsymedicineHumansRNA MessengerAdipose tissue GLUT-4 mRNA Metformin PCOS Adipose Tissue Female Humans RNA Messenger Subcutaneous Fat Metformin Polycystic Ovary Syndromemedicine.diagnostic_testbusiness.industryInsulinGlucose transporternutritional and metabolic diseasesMetforminMetforminEndocrinologyAdipose TissueFemaleSubcutaneous adipose tissuebusinessPolycystic Ovary Syndromemedicine.drug
researchProduct

Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications

2021

Preclinical studies provided some important insights into the action of glucagon-like peptide 1 (GLP-1) in taste perception. This review examines the literature to uncover some molecular mechanisms and connections between GLP-1 and the gustatory coding. Local GLP-1 production in the taste bud cells, the expression of GLP-1 receptor on the adjacent nerves, a functional continuum in the perception of sweet chemicals from the gut to the tongue and an identification of GLP-1 induced signaling pathways in peripheral and central gustatory coding all strongly suggest that GLP-1 is involved in the taste perception, especially sweet. However, the impact of GLP-1 based therapies on gustatory coding i…

0301 basic medicineTasteendocrine systemobesitymedia_common.quotation_subject030209 endocrinology & metabolismReviewBiologyCatalysisGlucagon-Like Peptide-1 Receptorlcsh:ChemistryInorganic Chemistrytaste03 medical and health sciences0302 clinical medicineTreatment targetsTonguetongueGlucagon-Like Peptide 1PerceptionmedicineAnimalsHumansGLP-1 Sweet Taste Tongue Animals Glucagon-Like Peptide-1 Receptor Humans Obesity Signal Transduction Taste Taste Buds Taste PerceptionPhysical and Theoretical ChemistryReceptorTaste Bud Cellslcsh:QH301-705.5Molecular BiologySpectroscopymedia_commonOrganic Chemistrydigestive oral and skin physiologyTaste PerceptionGeneral MedicineTaste BudsGlucagon-like peptide-1Computer Science Applications030104 developmental biologymedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999Signal transductionGLP-1Neurosciencesweethormones hormone substitutes and hormone antagonistsSignal TransductionInternational Journal of Molecular Sciences
researchProduct

Impact of COVID-19 Pandemic on Disease Control Status and Quality of Life of Patients with Acromegaly.

2022

Background and Objectives: Despite the best efforts of healthcare workers and the deployment of alternative healthcare delivery solutions through telemedicine, the pandemic has disrupted standard care for patients with chronic conditions. The long-lasting pandemic has also had a profound impact on the quality of life (QoL) of the majority of patients with chronic illnesses. The management of rare diseases has been particularly challenging. We aimed to evaluate the impacts that the long-lasting pandemic had on the disease control status and QoL in patients with acromegaly. Materials and Methods: Our prospective study included 34 patients from a national referral centre. The baseline SAGIT an…

SARS-CoV-2Surveys and QuestionnairesAcroQoL COVID-19 pandemic SAGIT instrument acromegaly disease control status public health measuresAcromegalyCommunicable Disease ControlQuality of LifeHumansRNA ViralCOVID-19General MedicineProspective Studiesacromegaly; disease control status; SAGIT instrument; AcroQoL; COVID-19 pandemic; public health measuresPandemicsMedicina (Kaunas, Lithuania)
researchProduct

Weight response to GLP-1 receptor agonists: Why women do it better?

2022

nessuno

diabetes obesityDipeptidyl-Peptidase IV InhibitorsEndocrinologyDiabetes Mellitus Type 2Endocrinology Diabetes and MetabolismInternal MedicineHumansHypoglycemic AgentsFemaleGlucagon-Like Peptide-1 ReceptorJournal of diabetes and its complications
researchProduct